pubmed.ncbi.nlm.nih.gov

Treatment of hemophilia: a review of current advances and ongoing issues - PubMed

Treatment of hemophilia: a review of current advances and ongoing issues

Antonio Coppola et al. J Blood Med. 2010.

Abstract

Replacement of the congenitally deficient factor VIII or IX through plasma-derived or recombinant concentrates is the mainstay of treatment for hemophilia. Concentrate infusions when hemorrhages occur typically in joint and muscles (on-demand treatment) is able to resolve bleeding, but does not prevent the progressive joint deterioration leading to crippling hemophilic arthropathy. Therefore, primary prophylaxis, ie, regular infusion of concentrates started after the first joint bleed and/or before the age of two years, is now recognized as first-line treatment in children with severe hemophilia. Secondary prophylaxis, whenever started, aims to avoid (or delay) the progression of arthropathy and improve patient quality of life. Interestingly, recent data suggest a role for early prophylaxis also in preventing development of inhibitors, the most serious complication of treatment in hemophilia, in which multiple genetic and environmental factors may be involved. Treatment of bleeds in patients with inhibitors requires bypassing agents (activated prothrombin complex concentrates, recombinant factor VIIa). However, eradication of inhibitors by induction of immune tolerance should be the first choice for patients with recent onset inhibitors. The wide availability of safe factor concentrates and programs for comprehensive care has now resulted in highly satisfactory treatment of hemophilia patients in developed countries. Unfortunately, this is not true for more than two-thirds of persons with hemophilia, who live in developing countries.

Keywords: bleeding; clotting factor concentrates; comprehensive care; hemophilia; inhibitors; prophylaxis; treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1

Factors contributing to inhibitor development in hemophilic patients. Multiple genetic and environmental factors interact during the first exposures to factor concentrate replacement treatment. Most data have been obtained from studies in hemophilia A patients, who develop inhibitors with higher frequency than those with hemophilia B.

Figure 2
Figure 2

Current treatment strategies for patients with hemophilia who develop inhibitors.

Similar articles

Cited by

References

    1. Mannucci PM, Tuddenham EG. The hemophilias – from royal genes to gene therapy. N Engl J Med. 2001;344(5):1773–1779. - PubMed
    1. van Dijk K, Fischer K, van der Bom JG, Grobbee DE, van den Berg HM. Variability in clinical phenotype of severe haemophilia: The role of the first joint bleed. Haemophilia. 2005;11(5):438–443. - PubMed
    1. Santagostino E, Mannucci PM, for the Italian Association of Haemophilia Centres (AICE) Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy. Haemophilia. 2000;6(1):1–10. - PubMed
    1. Rosendaal G, Lafeber FP. Pathogenesis of hemophilic arthropathy. Haemophilia. 2006;12(Suppl 3):117–121. - PubMed
    1. Mannucci PM. Back to the future: A recent history of hemophilia treatment. Haemophilia. 2008;14(Suppl 3):10–18. - PubMed